Drug intelligence / Profile preview

BSDO-2301

Development stage: Unknown
Lead developer: Hyundai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**BSDO-2301** is Hyundai Pharmaceutical's orally administered, small-molecule fixed-dose combination candidate for **mixed dyslipidemia**. The active-ingredient identities have not been publicly disclosed. It is being evaluated in a Korean multicenter, randomized, double-blind, active-controlled Phase 3 trial in 550 patients, assessing changes in non-HDL cholesterol and triglycerides and evaluating safety. The program previously completed a Phase 1 drug-interaction study.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on BSDO-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSDO-2301.

Explore the full profile